Mentari Therapeutics falls 19% on reverse split and name change

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Mentari Therapeutics (MTRI.US) fell nearly 19% during regular trading to $13.03.

The company completed a 1-for-10 reverse stock split on Nov. 4, 2026, reducing outstanding shares to approximately 549,374 from about 5.49 million, and changed its name from InMed Pharmaceuticals to Mentari Therapeutics.

The company outlined development plans for its migraine drug pipeline. It intends to file a regulatory application for candidate MT-002 in the first quarter of 2027 and expects to release Phase 1 clinical data by year-end.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings